- Male or female at least 18 years of age available for a follow-up period of at least
- HIV 1 RNA viral load of greater then 500 copies/mL.
- Negative urine pregnancy test.
- Suspected or documented active, untreated HIV-1 related opportunistic infection or
other condition requiring acute therapy at the time of randomization.
- Subjects with acute Hepatitis B and/or C within 30 days of randomization.
- Previous use of Darunavir or etravirine